{"task_id": "e0d56656e72745f8", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 287/464)", "text": "\u0002\nTEMPOROMANDIBULAR (30%)\nRheumatoid Arthritis\n277\n\n--- Page 299 ---\nCLINICAL FEATURES (CONT\u2019D)\n\u0002\nOTHERS\nrelated disorders include Baker cyst,\ntenosynovitis, carpal tunnel syndrome\nRelated Topics\nGout (p. 275)\nInflammatory Myositis (p. 281)\nLupus (p. 280)\nScleroderma (p. 281)\nEXTRA ARTICULAR\nMANIFESTATIONS\nonly\nin\nrheumatoid factor seropositive patients\n\u0002\nRHEUMATOID NODULES (20%)\n\u0002\nPULMONARY\npleural effusion (exudates, low glu\ncose), pulmonary nodules (Caplan\u2019s syndrome),\nacute\ninterstitial\npneumonitis,\nbronchiolitis\nobliterans\n\u0002\nCARDIAC\nvalvular\nabnormalities,\nmyocarditis,\npericardial effusion, constrictive pericarditis\n\u0002 GI\nelevated\ntransaminases (especially ALP),\nnodular\nhyperplasia\n(portal\nhypertension,\nhypersplenism)\n\u0002\nHEMATOLOGIC\nanemia of chronic disease, Felty\nsyndrome\n(triad\nof\nseropositive\nrheumatoid\narthritis, neutropenia often associated with ane\nmia and thrombocytopenia and splenomegaly.\nPatients at risk of life threatening bacterial infec\ntions). Large granular lymphocyte leukemia,\nlymphoma\n\u0002\nNEUROLOGIC\nperipheral sensory neuropathy (not\nmotor),\nmyelopathy\nfrom\ncervical\nvertebral\nsubluxation\n\u0002\nOPHTHALMIC\nkeratoconjunctivitis sicca (Sjogren\u2019s\nsyndrome), scleritis, episcleritis\n\u0002\nDERMATOLOGIC\nvasculitis (digital arteritis, cuta\nneous ulceration, visceral arteritis)\n\u0002\nOTHERS\namyloidosis\nCONSTITUTIONAL\nSYMPTOMS\nfatigue\n(40%),\nfever (low grade), sweats, weight loss, myalgia\nDISTINGUISHING FEATURES BETWEEN\nINFLAMMATORY AND NON INFLAMMATORY\nARTHRITIS\nInflammatory Non\ninflammatory\nClassic example\nRA\nOA\nMorning stiffness\n>1 h\n+/\nResting\nWorsens\nImproves\nActivity\nImproves\nWorsens\nSynovitis, redness\n+\nFever, weight loss\n+\nESR, CRP,\nplatelets\n\"\nNo change\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, AST, ALT, ALP, bilir\nubin, ESR, CRP, RF (IgM), anti CCP (more speci\nfic), ANA, urinalysis\n\u0002\nIMAGING\nX rays of affected joints (particularly\nhands, knees, and ankles; soft tissue swelling,\nperiarticular osteopenia, narrowing of joint\nspace, marginal bony erosions, subluxation,\njoint destruction, bony ankylosis)\nSPECIAL\n\u0002\nINFECTIOUS\nWORKUP\nserologies\n(Parvovirus,\nHBV, HCV, EBV, CMV, Borrelia burgdorferi)\n\u0002\nARTHROCENTESIS\nw3Cw (Cell count with diff\n[>2000 WBC/mm3], Culture and Gram stain,\nCrystal. Cannot make definite diagnosis of rheu\nmatoid arthritis from arthrocentesis)\nDIAGNOSTIC AND PROGNOSTIC ISSUES\nACR DIAGNOSTIC CRITERIA FOR RHEUMATOID\nARTHRITIS\nmorning stiffness (>1 h), arthritis of\n\u00043 joint areas (either side of PIP, MCP, wrist, elbow,\nknee, ankle, and MTP), arthritis of hand joints (PIP,\nMCP), symmetric arthritis by area, subcutaneous\nrheumatoid nodules, positive rheumatoid factor,\nradiographic changes (hand and wrist X ray with\nerosion of joints or unequivocal demineralization\naround joints). Need 4 of 7 criteria to make diagnosis,\nwith first 4 criteria for at least 6 weeks\nPROGNOSIS\nincreased number of joints involved,\npresence of rheumatoid nodules and seropositivity all\nsuggest more severe disease\nMANAGEMENT\nSYMPTOM CONTROL\nphysical therapy, diet (O 3\nand O 6 fatty acids). Joint protection (range of\nmotion exercises, orthotics, splints). NSAIDs (anti\ninflammatory dose). Intraarticular steroid injec\ntions (if severe pain). Patient education\nDISEASE MODIFYING AGENTS OF RHEUMATOID\nDISEASE (DMARDs)\nsingle agent (methotrexate\nwith folic acid, sulfasalazine, hydroxychloroquine,\nminocycline, cyclosporine, azathioprine, gold). Com\nbination triple therapy (methotrexate plus sulfasa\nlazine plus hydroxychloroquine). Selective pyrimi\ndine\nsynthesis\ninhibitor\n(leflunomide).\nTNFa\ninhibitors (infliximab, etanercept, adalimumab). B\ncell inhibitor (rituximab, an anti CD20 monoclonal\nantibody). T lymphocyte activation inhibitor (aba\ntacept). Surgical intervention\nSPECIFIC ENTITIES\nPALINDROMIC RHEUMATISM\nepisodic arthritis\nwith one or more joints being affected sequentially\nfor hours to days, and symptom free periods in\n278\nRheumatoid Arthritis", "text_length": 3911, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 287/464)", "type": "chunk", "chunk_index": 286, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.640038", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.640754", "status": "complete", "chunks_added": 3}